Hello, my name is Haaziq Ali from the University of Nevada, Reno and Sierra Eye Associates in Reno, Nevada. And here at ARVO 2026 in Denver, I presented the three-year results of the TAHOE study, a real-world study investigating the efficacy and safety of faricimab in patients with diabetic macular edema. As you know, our investigator-led sponsor-free study has been independently evaluating real-world DME patients all over the country treated with faricimab and primarily includes previously treated patients.

In three years, we have recorded approximately 5,885 injections across over 660 patients. In all previously treated in aflibercept switch patients, results demonstrate improvements in CST of about 11 to 24 microns after just one treatment of faricimab. After three injections of faricimab, we see a steady decrease in fluid and a steady maintenance of visual acuity. This trend is followed similarly when looking at six injections of faricimab. In our treatment naive patients, we see a statistically significant improvement in visual acuity after just one injection of faricimab.

We see a significant improvement in fluid with a reduction of almost 50 microns and a visual acuity gain of six letters. By three injections, we see a large improvement in visual acuity with an almost 10 letter gain and a 92 micron reduction of fluid. This trend continues with the sixth injection showing significant improvements in visual acuity and a reduction in CST. To date, the TAHOE study has demonstrated a strong safety profile with no reported cases of endophthalmitis, vasculitis, or retinal artery occlusions across nearly 6,000 injections.

The TAHOE study has continued to show significant improvements in anatomical parameters in all demographics of patients, highlighting the benefit of dual inhibition of Ang2 and VEGF. We look forward to the continued long-term data of faricimab in patients with DME. I want to thank our investigators and their teams for their relentless efforts and dedication. Thank you for your time.